Trial reportClinical autonomic research : official journal of the Clinical Autonomic Research Society2006
Treatment of postural tachycardia syndrome: a comparison of octreotide and midodrine.
Trial report in Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Systematic literature review: treatment of postural orthostatic tachycardia syndrome (POTS).Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026Pooled it
- Abdominal-only Compression Garments Reduce Orthostatic Tachycardia and Improve Symptoms in Patients With Postural Orthostatic Tachycardia Syndrome.The Canadian journal of cardiology · 2026Trial
- Efficacy of Propranolol, Bisoprolol, and Pyridostigmine for Postural Tachycardia Syndrome: a Randomized Clinical Trial.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2018Trial
- A double-blind placebo-controlled cross-over study of the vascular effects of midodrine in neuropathic compared with hyperadrenergic postural tachycardia syndrome.Clinical science (London, England : 1979) · 2014Trial
- A somatostatin analog improves tilt table tolerance by decreasing splanchnic vascular conductance.Journal of applied physiology (Bethesda, Md. : 1985) · 2012Trial
- Effect of octreotide on postmenopausal hot flushes.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2009Trial
- A Randomized Crossover Trial of Ivabradine, Propranolol, and Placebo in Postural Orthostatic Tachycardia Syndrome: A Detailed Description.JACC. Advances · 2026Article
- Choices and Challenges With Drug Therapy in Postural Orthostatic Tachycardia Syndrome: A Systematic Review.Cureus · 2023Review
- Orthostatic heart rate does not predict symptomatic burden in pediatric patients with chronic orthostatic intolerance.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2020Article
- Water Ingestion in Postural Orthostatic Tachycardia Syndrome: A Feasible Treatment Option?The Journal of innovations in cardiac rhythm management · 2019Article
- Review
- Postural Tachycardia Syndrome: Beyond Orthostatic Intolerance.Current neurology and neuroscience reports · 2015Review
- Treatment of Refractory Postural Tachycardia Syndrome with Subcutaneous Octreotide Delivered Using an Insulin Pump.Case reports in medicine · 2015Article
- Difference between supine and upright blood pressure associates to the efficacy of midodrine on postural orthostatic tachycardia syndrome (POTS) in children.Pediatric cardiology · 2014Article
- Neuronal and hormonal perturbations in postural tachycardia syndrome.Frontiers in physiology · 2014Review
- Postural tachycardia syndrome--current experience and concepts.Nature reviews. Neurology · 2011Review
- The location of the human volume indifferent point predicts orthostatic tolerance.European journal of applied physiology · 2010Article
- Cardiac denervation in postural tachycardia syndrome.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2008Article
- Takotsubo cardiomyopathy in a patient with postural tachycardia syndrome.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2008Article
- Treatment of autonomic neuropathy, postural tachycardia and orthostatic syncope with octreotide LAR.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We assessed the potency of octreotide and midodrine, and their combination, in the treatment of the postural tachycardia syndrome (POTS) and orthostatic intolerance (OI). Nine patients with POTS and six patients with OI stood for up to 1 hour while their HR and BP were monitored. Patients received on separate days, midodrine 10 mg 1 hour before testing, octreotide 0.9 micro g/kg 8 minutes before testing or combination therapy. Standing time in the patients with POTS was 41.2 +/- 8.4 minutes and not improved by midodrine or octreotide, but increased to 56.3 +/- 2.7 (P < 0.01) minutes following combination therapy. The standing heart rate in POTS, 114 +/- 0.7 bpm, was suppressed by midodrine 92.8 +/- 0.7 (P < 0.001), octreotide 90.6 +/- 0.78 (P < 0.001), and combination therapy 84.7 +/- 0.7 (P < 0.001). Combination therapy was better than monotherapy (P < 0.001) but only for the first 10 minutes of standing. Standing time of 36.3 +/- 3.5 minutes in the patients with OI improved with midodrine, octreotide and combination therapy (55.5 +/- 3.1, 56.5 +/- 3.5, and 56.6 +/- 3.3, respectively, P < 0.05 for each). Standing heart rate in OI was 100 +/- .76 bpm; following midodrine it was 80.3 +/- .69 (P < 0.05), following octreotide it was 84.8 +/- .86, and following combination therapy it was 71.2 +/- .9 (P < 0.01). The RR interval versus time area under the curve (The Orthostatic Index) was 21.1 +/- 4 in patients with OI. After midodrine it was 41.4 +/- 3.5 (P < 0.01), after octreotide 40.3 +/- 3.8 (P < 0.01) and after the combination it was 47.3 +/- 4.6 (P < 0.001). Midodrine and octreotide suppressed tachycardia in POTS and improved standing times in OI. The two drugs had similar potencies; combination therapy was not significantly better than monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.